| Literature DB >> 35456834 |
Han-Yin Hsu1, Yi-Chu Liao1, Shih-Hsuan Lin1, Jin-Seng Lin1, Chia-Chia Lee1, Koichi Watanabe1,2.
Abstract
Lactiplantibacillus plantarum TWK10 (TWK10), isolated from Taiwanese pickled cabbage, has been demonstrated to exert beneficial probiotic effects in both mice and humans. Here, we comprehensively assessed the safety of TWK10 using both in vivo and in vitro approaches, including whole-genome sequence analysis, an assessment of hemolytic activity, and performing an antimicrobial susceptibility test, the Ames bacterial reverse mutation assay, the chromosomal aberration test, a rodent peripheral blood micronucleus test, and the 28-day subacute oral toxicity assay. The results showed that there was no significant increase in the incidence of reverse mutations or chromosomal aberrations following exposure to TWK10. Moreover, no significant changes were detected either in the number of reticulocytes or the incidence of micronuclei in ICR mice, and no subacute toxicity was recorded in SD rats at the oral TWK10 dosage of 2000 mg/kg body weight/day repeated for 28 days. Additionally, TWK10 exhibited no hemolytic activity and was susceptible to all the antibiotics tested, except kanamycin. However, no antimicrobial resistance genes, virulence factors, or genes involved in biogenic amine synthesis were found in the genome of TWK10. Our findings demonstrated that TWK10 has high potential of being safe for human consumption as a probiotic.Entities:
Keywords: Lactiplantibacillus plantarum TWK10; Lactobacillus plantarum TWK10; genotoxicity; oral toxicity; probiotics; safety assessment; whole-genome sequencing
Year: 2022 PMID: 35456834 PMCID: PMC9031848 DOI: 10.3390/microorganisms10040784
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Comparison of the genomic features of Lactiplantibacillus plantarum strains TWK10, ATCC 14917T, and WCFS1.
| Strain | |||
|---|---|---|---|
| TWK10 | ATCC 14917T | WCFS1 | |
| Accession No. | GCA_000143745.1 | GCA_000203855.3 | |
| Genome size (bp) | 3,273,862 | 3,212,261 | 3,348,624 |
| G + C content (%) | 44.4 | 44.5 | 44.4 |
| No. of contigs | 5 | 9 | 4 |
| N50 length (bp) | 3,205,949 | 152,365 | 3,308,273 |
| L50 | 1 | 6 | 1 |
| Genes | 3173 | 3061 | 3211 |
| CDS | 3088 | 2999 | 3123 |
| tRNA | 68 | 59 | 71 |
| rRNA | 16 | 2 | 16 |
| tmRNA | 1 | 1 | 1 |
Bp, base pairs; CDS, coding sequence; tRNA, transfer RNA; rRNA, ribosomal RNA; tmRNA, transfer-messenger RNA.
The antimicrobial sensitivity of TWK10.
| Antibiotics | MIC a | Cut-Off Value b | Sensitivity c | Antimicrobial Resistance Gene |
|---|---|---|---|---|
| Ampicillin | <0.5 | 2 | S | ND d |
| Gentamicin | 16 | 16 | S | ND |
| Kanamycin | 128 | 64 | R | ND |
| Erythromycin | <0.5 | 1 | S | ND |
| Clindamycin | 2 | 4 | S | ND |
| Tetracycline | 16 | 32 | S | ND |
| Chloramphenicol | 4 | 8 | S | ND |
a MIC, minimal inhibitory concentration (mg/L) toward TWK10. b Microbiological cut-off values (mg/L) for antibiotics recommended by the European Food Safety Authority. c S, Susceptible; R, Resistant. d ND, not detected.
Ames test results for TWK10 using S. Typhimurium strains.
| Number of Revertant Colonies/Plate | |||||
|---|---|---|---|---|---|
| TA98 | TA100 | TA102 | TA1535 | TA1537 | |
|
| |||||
| Negative control a | 25 ± 5 | 211 ± 8 | 428 ± 16 | 16 ± 4 | 9 ± 3 |
| Positive control b | 388 ± 41 * | 650 ± 11 * | 859 ± 40 * | 284 ± 22 * | 303 ± 14 * |
| TWK10 (5.0000 mg) | 23 ± 1 | 202 ± 9 | 425 ± 27 | 14 ± 1 | 7 ± 1 |
| TWK10 (2.5000 mg) | 27 ± 2 | 210 ± 5 | 423 ± 9 | 17 ± 4 | 9 ± 2 |
| TWK10 (1.2500 mg) | 31 ± 2 | 212 ± 7 | 421 ± 25 | 17 ± 5 | 10 ± 2 |
| TWK10 (0.6250 mg) | 28 ± 4 | 212 ± 7 | 447 ± 32 | 18 ± 1 | 10 ± 3 |
| TWK10 (0.3125 mg) | 28 ± 2 | 217 ± 1 | 430 ± 19 | 19 ± 7 | 14 ± 3 |
|
| |||||
| Negative control a | 21 ± 3 | 171 ± 7 | 371 ± 26 | 17 ± 3 | 9 ± 2 |
| Positive control c | 265 ± 20 * | 616 ± 52 * | 770 ± 24 * | 221 ± 12 * | 245 ± 18 * |
| TWK10 (5.0000 mg) | 22 ± 1 | 175 ± 6 | 368 ± 31 | 20 ± 1 | 8 ± 3 |
| TWK10 (2.5000 mg) | 25 ± 1 | 178 ± 16 | 373 ± 5 | 17 ± 1 | 8 ± 3 |
| TWK10 (1.2500 mg) | 29 ± 3 | 179 ± 11 | 358 ± 24 | 18 ± 2 | 7 ± 2 |
| TWK10 (0.6250 mg) | 28 ± 4 | 185 ± 15 | 359 ± 29 | 15 ± 1 | 8 ± 2 |
| TWK10 (0.3125 mg) | 29 ± 2 | 169 ± 18 | 375 ± 16 | 21 ± 2 | 8 ± 3 |
Data are presented as means ± SD (n = 3). Statistically significant differences between the number of revertant colonies of each column and that of the negative control were calculated using one-way ANOVA with Dunnett’s post hoc test. The asterisk (*) indicates a significant difference relative to the negative control (p < 0.05). a Sterile water was used as a negative control. b Positive controls with S9 for TA98: benzo[α]pyrene, 4 μg/plate; for TA100: 2-aminoanthracene, 4 μg/plate; for TA102: 2-aminoanthracene, 10 μg/plate; for TA1535: 2-aminoanthracene, 4 μg/plate; for TA1537: 2-aminoanthracene, 4 μg/plate. c Positive controls without S9 for TA98: 4-nitroquinoline 1-oxide, 0.5 μg/plate; for TA100: sodium azide, 5.0 μg/plate; for TA102: mitomycin C, 0.5 μg/plate; for TA1535: sodium azide, 0.4 μg/plate; for TA1537: 9-aminoanthracene, 50.0 μg/plate.
Chromosomal aberration test for TWK10 in CHO-K1 cells.
| Number of Chromosome Aberrations | Total Number of Chromosomal Aberrations (%) | Number of Cells with Chromosomal Aberrations (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (Per 100 Cells) | |||||||||||
| G | B | D | R | g | b | Int | Itr | Other | |||
|
| |||||||||||
| Negative control a | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1.0 | 1.0 |
| Positive control b | 2.5 | 1.5 | 0 | 0.5 | 4 | 2 | 0.5 | 0 | 2.5 | 13.5 | 13.5 |
| TWK10 (5.00 mg/mL) | 0 | 0 | 0 | 0.5 | 1 | 0 | 0 | 0 | 0 | 1.5 | 1.5 |
| TWK10 (2.50 mg/mL) | 0 | 0 | 0 | 0 | 1.5 | 0.5 | 0 | 0 | 0 | 2.0 | 1.5 |
| TWK10 (1.25 mg/mL) | 0 | 0 | 0 | 0 | 0.5 | 1 | 0 | 0 | 0 | 1.5 | 1.5 |
|
| |||||||||||
| Negative control a | 0 | 0 | 0 | 0 | 1.5 | 0.5 | 0 | 0 | 0 | 2.0 | 1.0 |
| Positive control c | 2 | 0.5 | 0 | 0.5 | 4.5 | 2.5 | 0.5 | 0 | 2 | 12.5 | 12.5 |
| TWK10 (5.00 mg/mL) | 0 | 0.5 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0.5 | 1.5 | 1.5 |
| TWK10 (2.50 mg/mL) | 0 | 0 | 0 | 0 | 1.5 | 0.5 | 0 | 0 | 0 | 2.0 | 2.0 |
| TWK10 (1.25 mg/mL) | 0 | 0 | 0 | 0 | 0.5 | 0.5 | 0 | 0 | 0 | 1.0 | 1.0 |
|
| |||||||||||
| Negative control a | 0 | 0 | 0 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 1.0 | 1.0 |
| Positive control c | 2 | 0.5 | 0.5 | 0.5 | 4.5 | 2.5 | 0 | 0 | 2 | 12.5 | 12.5 |
| TWK10 (5.00 mg/mL) | 0 | 0 | 0 | 0 | 1.5 | 0.5 | 0 | 0 | 0 | 2.0 | 1.5 |
| TWK10 (2.50 mg/mL) | 0 | 0 | 0 | 0 | 0.5 | 0.5 | 0 | 0 | 1 | 2.0 | 1.5 |
| TWK10 (1.25 mg/mL) | 0.5 | 0.5 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2.0 | 2.0 |
Data are the average of duplicate measurements. a Ham’s F-12 medium with 10% fetal bovine serum. b 25 μg/mL cyclophosphamide monohydrate was used with S9. c 2.5 μg/mL mitomycin C was used without S9. G, chromosome gap; B, chromosome break; D, dicentric; R, ring; g, chromatid gap; b, chromatid break; Int, interchange; Itr, intrachange; other, polyploidy cell and cell with endoreduplication or centromeric disruption.
Reticulocyte ratio and micronucleus incidence in peripheral blood of ICR mice administered TWK10.
| Reticulocyte Ratio a | Micronucleus Incidence b | ||||
|---|---|---|---|---|---|
| Median | Median | ||||
| (Q1–Q3) c | (Q1–Q3) c | ||||
|
| |||||
| Negative control d | 46 (42.5–46.5) | – | 0 (0.0–1.0) | – | |
| Positive control e | 15 (13.5–18.0) | 0.008 * | 17 (15.5–18.5) | 0.008 * | |
| TWK10 (500 mg/kg BW) | 46 (41.0–49.0) | 0.889 | 1 (0.0–1.5) | 0.683 | |
| TWK10 (1000 mg/kg BW) | 43 (41.0–48.5) | 0.984 | 1 (0.0–1.5) | 0.683 | |
| TWK10 (2000 mg/kg BW) | 45 (41.5–45.5) | 0.437 | 1 (0.5–1.5) | 0.365 | |
|
| |||||
| Negative control d | 47 (46.5–48.5) | – | 1 (0.0–1.5) | – | |
| Positive control e | 17 (16.5–18.5) | 0.008 * | 15 (14.5–17.0) | 0.008 * | |
| TWK10 (500 mg/kg BW) | 47 (45.5–48.0) | 0.619 | 1 (0.0–1.5) | 1.000 | |
| TWK10 (1000 mg/kg BW) | 47 (46.0–48.5) | 0.881 | 1 (0.5–1.5) | 0.881 | |
| TWK10 (2000 mg/kg BW) | 47 (45.5–47.5) | 0.444 | 1 (0.5–1.5) | 0.881 | |
a Reticulocyte ratio, reticulocytes (RETs)/1000 red blood cells (RBCs); n = 5. b Micronucleus incidence, reticulocytes with micronucleus (Mn-RET)/1000 reticulocytes (RETs); n = 5. c Q1, 25% quartile; Q3, 75% quartile. d Sterile water was used as the negative control. e Cyclophosphamide monohydrate at 50 mg/kg body weight served as the positive control. Statistically significant differences between the median values of each column and the negative control were calculated using the Kruskal–Wallis test with Dunn’s post hoc test. The asterisk (*) indicates a significant difference compared with the negative control (p < 0.05).
Body weight and organ weight of Sprague–Dawley rats administered TWK10 for 28 days.
| Male | ||||
| Control | Low Dose | Medium Dose | High Dose | |
| Body weight (before) | 207.6 ± 9.8 | 207.6 ± 8.9 | 207.6 ± 8.4 | 207.7 ± 7.7 |
| Body weight (after) | 377.8 ± 29.3 | 362.6 ± 29.7 | 370.9 ± 18.5 | 351.3 ± 25.6 |
| Testis | 3.236 ± 0.281 | 3.284 ± 0.251 | 3.325 ± 0.207 | 3.330 ± 0.184 |
| Adrenal gland | 0.075 ± 0.016 | 0.070 ± 0.014 | 0.073 ± 0.014 | 0.073 ± 0.014 |
| Spleen | 0.731 ± 0.086 | 0.677 ± 0.154 | 0.720 ± 0.118 | 0.661 ± 0.128 |
| Kidney | 3.438 ± 0.360 | 3.198 ± 0.280 | 3.396 ± 0.260 | 3.198 ± 0.327 |
| Heart | 1.528 ± 0.183 | 1.486 ±0.114 | 1.510 ± 0.130 | 1.435 ± 0.173 |
| Brain | 2.075 ± 0.062 | 1.971 ± 0.120 * | 2.030 ± 0.063 | 2.024 ± 0.078 |
| Liver | 15.027 ± 1.653 | 13.803 ± 1.226 | 14.672 ± 1.132 | 14.194 ± 1.752 |
| Female | ||||
| Control | Low dose | Medium dose | High dose | |
| Body weight (before) | 179.4 ± 8.0 | 178.0 ± 8.9 | 180.0 ± 8.6 | 181.0 ± 8.6 |
| Body weight (after) | 221.8 ± 16.5 | 232.1 ± 11.5 | 227.5 ± 20.8 | 232.9 ± 15.5 |
| Ovary | 0.117 ± 0.021 | 0.121 ± 0.034 | 0.121 ± 0.038 | 0.111 ± 0.024 |
| Adrenal gland | 0.073 ± 0.010 | 0.082 ± 0.010 | 0.074 ± 0.011 | 0.080 ± 0.010 |
| Spleen | 0.426 ± 0.088 | 0.514 ± 0.080 | 0.499 ± 0.074 | 0.509 ± 0.074 |
| Kidney | 1.952 ± 0.131 | 2.026 ± 0.127 | 2.083 ± 0.272 | 2.046 ± 0.171 |
| Heart | 0.980 ± 0.080 | 1.009 ± 0.081 | 0.985 ± 0.131 | 0.969 ± 0.093 |
| Brain | 1.921 ± 0.066 | 1.895 ± 0.073 | 1.927 ± 0.079 | 1.881 ± 0.083 |
| Liver | 8.512 ± 0.952 | 8.902 ± 0.943 | 8.718 ± 1.424 | 8.601 ± 0.848 |
Data are presented as means ± SD, n = 10. Statistically significant differences between the body weight and absolute organ weight of each group and those of the control group were calculated using one-way ANOVA with Tukey’s post-hoc test. The asterisk (*) indicates a significant difference relative to the control group (p < 0.05). BW, body weight.